drugset / Trial / NCT07562087
A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure
Phase 2
Active not recruiting
722 enrolled
Tarsus Pharmaceuticals, Inc.
PPD Development, LP · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This study is designed to evaluate the safety, tolerability, and pharmacokinetics of TP05 administered orally to healthy adult participants.
Timeline
- Start
- 2026-03-09
- Primary completion
- 2027-10
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | lotilaner | Small molecule | — | Oral |